Understanding a BRCA2 positive diagnosis? This resource provides essential information for healthcare professionals on BRCA2 mutations, including BRCA2 genetic susceptibility. Learn about clinical documentation best practices and medical coding guidelines related to a BRCA2 positive result for accurate and comprehensive patient care. Find details on BRCA2 mutation testing, risk assessment, and management strategies.
Also known as
Genetic susceptibility to malignant neoplasm of breast
Increased risk of breast cancer due to inherited genetic factors.
Family history of malignant neoplasm of breast
Personal history of a family member with breast cancer.
Genetic susceptibility to other malignant neoplasms
Increased risk of other cancers due to inherited genetic factors.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is BRCA2 definitively positive?
When to use each related code
| Description |
|---|
| Increased risk of breast, ovarian, and other cancers. |
| Increased risk of breast and ovarian cancer. |
| Variant of uncertain significance found in BRCA1/2 gene. |
Coding requires specifying if the BRCA2 mutation is deleterious (disease-causing) or a variant of unknown significance (VUS) for accurate risk assessment and medical necessity.
Missing documentation of laterality (e.g., left, right, bilateral) for prophylactic mastectomy or oophorectomy based on BRCA2 status may lead to claim denials.
Conflicting or missing family history documentation related to breast/ovarian cancer can affect the medical necessity of BRCA2 testing and related preventative procedures, triggering audits.
Q: What are the most current evidence-based screening and risk reduction strategies for patients with a BRCA2 positive result?
A: Managing patients with a BRCA2 positive result requires a comprehensive approach based on current evidence-based guidelines. For female patients, this includes enhanced breast cancer surveillance with annual mammograms and breast MRIs, often starting at an earlier age than the general population. Consider implementing risk-reducing strategies such as chemoprevention with medications like tamoxifen or raloxifene, or discussing the option of prophylactic mastectomy. Male BRCA2 carriers have an increased risk of breast cancer and prostate cancer, so individualized screening protocols should be discussed. For both genders, genetic counseling is crucial to discuss family planning and cascade testing for relatives. Explore how the National Comprehensive Cancer Network (NCCN) guidelines provide detailed recommendations tailored to BRCA2 carriers.
Q: How do I interpret and explain the clinical significance of a BRCA2 mutation detected through genetic testing to a patient in a clear and empathetic way?
A: Explaining the clinical significance of a BRCA2 mutation requires clear and empathetic communication. First, reiterate that a positive BRCA2 result does not equate to a cancer diagnosis, but signifies an increased predisposition to certain cancers, including breast, ovarian, prostate, and pancreatic. It's important to quantify this risk with personalized risk assessments based on factors like age, family history, and specific mutation. Discuss the available screening and risk reduction options tailored to the individual's situation. Providing resources such as support groups and educational materials can also be beneficial. Learn more about effective communication strategies for delivering complex genetic information and addressing patient anxieties.
Patient presents for genetic counseling and evaluation of BRCA2 mutation status due to family history of breast cancer, ovarian cancer, and prostate cancer. Genetic testing via multigene panel revealed a pathogenic variant in the BRCA2 gene, confirming a diagnosis of BRCA2 positive status. This BRCA2 genetic susceptibility increases the patient's lifetime risk of developing breast cancer, ovarian cancer, fallopian tube cancer, primary peritoneal cancer, prostate cancer, pancreatic cancer, and melanoma. Discussed risk-reducing strategies including increased surveillance with breast MRI and mammogram, prophylactic mastectomy, prophylactic salpingo-oophorectomy, and chemoprevention options. Patient understands the implications of this BRCA2 mutation and the importance of genetic counseling for family members. Referred to a high-risk breast clinic and oncology for further evaluation and management. ICD-10 code Z15.01 (Genetic susceptibility to malignant neoplasm of breast) and Z15.02 (Genetic susceptibility to malignant neoplasm of ovary) are applicable. CPT codes for genetic testing and counseling were reviewed and documented. Patient education materials on hereditary breast and ovarian cancer syndrome (HBOC) were provided. Follow-up scheduled to discuss management plan in detail.